How Can You Realize the Promise of Theranostics?

Theranostics—the combination of radiopharmaceutical therapeutics and diagnostics—is a rapidly evolving treatment approach that offers new promise for precise, individualized healthcare. Experts predict that Theranostics will continue growing and will likely be used to treat a wider range of cancers and other diseases in the coming years.¹

While Theranostics holds great promise, that promise can remain unrealized without the right infrastructure, capacity, workforce, and best practice evidence. These factors can ultimately lead to inconsistent access. For instance, individuals in lower-income countries have less access to radiopharmaceutical therapies—other than ¹³³I— than those in higher-income countries,² and rural communities often have less access to cancer care compared to urban communities.³

Health systems around the world are known to be dealing with resource limitations in the face of  increasing caseloads, further hindering the implementation of emerging technologies. Additionally, even organizations with sufficient resources may struggle to translate rapidly evolving evidence around Theranostics into clinical practice.

Increase Theranostics Access by Empowering Healthcare Organizations

At MIM Software, a GE HealthCare Company, we believe that a key way to expand Theranostics access is to give healthcare organizations tools that make a smooth-running Theranostics practice attainable. Practical image-processing tools that help unearth patient-specific insights can play a critical role in helping clinics deliver high-quality Theranostics care with confidence, from patient referral to diagnosis to treatment. Automating otherwise time-consuming tasks by leveraging AI and background processing can also free up valuable time for clinicians to serve more patients. By empowering more clinics with innovative efficiency and confidence-boosting tools, we hope to ensure that more people can gain access to high-quality personalized Theranostics care, regardless of their country’s gross domestic product or their proximity to a major city.

You don’t have to look far to find examples of healthcare organizations using vendor-neutral imaging tools to expand access to advanced Theranostics care. 

At Hospital Angeles Health System, the largest private health system in Mexico, MIM Software tools help the 27-hospital network offer personalized Theranostics care to more patients throughout the region. Automation and standardization enabled by these software tools, which work with the various scanner manufacturers and imaging modalities used throughout the system, help Hospital Angeles increase its efficiency and reach more patients.  

In a recent episode of the Imaging Wire Show, three renowned clinicians—two Nuclear Medicine physicians and one radiation oncologist—discuss the promises and challenges of Theranostics. While each clinician shares a unique perspective, they all highlight the role that MIM solutions have played in helping them integrate Theranostics into their practices. One clinician notes that MIM tools are helping their organization expand its Theranostics practice beyond its main hospital into all centers in the network. As a result, Theranostics care will be available in both rural and urban communities in the region. 

Unlock the Opportunities of Precision Care with Theranostics

Wherever a healthcare organization is in its Theranostics journey, the right imaging and image processing tools can help unlock the opportunities that Theranostics promises. A key part of MIM Software’s mission is enabling greater access around the world to precise, personalized diagnostic and treatment options. We’re passionate about continuing to make precision care attainable—for healthcare organizations and the patients they serve.  

Footnotes

1. Burkett BJ, Bartlett DJ, McGarrah PW, et al. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiol Imaging Cancer. 2023;5(4):e220157.
2. Abdel-Wahab M, Giammarile F, Carrara M, et al. Radiotherapy and theranostics: a Lancet Oncology Commission. Lancet Oncol. 2024;25(11):e545-e580.
3. Munhoz R, Sabesan S, Thota R, Merrill J, Hensold JO. Revolutionizing Rural Oncology: Innovative Models and Global Perspectives. Am Soc Clin Oncol Educ Book. 2024;44(3):e432078.